4.8 Article

Mice Expressing Activated PI3K Rapidly Develop Advanced Colon Cancer

期刊

CANCER RESEARCH
卷 72, 期 12, 页码 2931-2936

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-11-4097

关键词

-

类别

资金

  1. Conquer Cancer Foundation of the American Society of Clinical Oncology through a Young Investigator Award
  2. National Cancer Institute of the U.S. NIH [P01 AI084853, P30 CA014520, P50 CA095103, R01 CA123438, T32 CA009614, T32 CA009135, T32 CA090217]
  3. Division of Gastroenterology and Hepatology
  4. Department of Medicine
  5. School of Medicine and Public Health at the University of Wisconsin

向作者/读者索取更多资源

Aberrations in the phosphoinositide 3-kinase (PI3K) signaling pathway play a key role in the pathogenesis of numerous cancers by altering cellular growth, metabolism, proliferation, and apoptosis. Mutations in the catalytic domain of PI3K that generate a dominantly active kinase are commonly found in human colorectal cancers and have been thought to drive tumor progression but not initiation. However, the effects of constitutively activated PI3K upon the intestinal mucosa have not been previously studied in animal models. Here, we show that the expression of a dominantly active form of the PI3K protein in the mouse intestine results in hyperplasia and advanced neoplasia. Mice expressing constitutively active PI3K in the epithelial cells of the distal small bowel and colon rapidly developed invasive adenocarcinomas in the colon that spread into the mesentery and adjacent organs. The histologic characteristics of these tumors were strikingly similar to invasive mucinous colon cancers in humans. Interestingly, these tumors formed without a benign polypoid intermediary, consistent with the lack of aberrant WNT signaling observed. Together, our findings indicate a noncanonical mechanism of colon tumor initiation that is mediated through activation of PI3K. This unique model has the potential to further our understanding of human disease and facilitate the development of therapeutics through pharmacologic screening and biomarker identification. Cancer Res; 72(12); 2931-6. (C)2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pharmacology & Pharmacy

DNA vaccines for prostate cancer

Christopher D. Zahm, Viswa Teja Colluru, Douglas G. McNeel

PHARMACOLOGY & THERAPEUTICS (2017)

Article Oncology

Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells

Christopher D. Zahm, Viswa T. Colluru, Douglas G. McNeel

CANCER IMMUNOLOGY RESEARCH (2017)

Article Oncology

TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells

Christopher D. Zahm, Viswa T. Colluru, Sean J. McIlwain, Irene M. Ong, Douglas G. McNeel

CANCER IMMUNOLOGY RESEARCH (2018)

Article Oncology

FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Matthew Scarpelli, Christopher Zahm, Scott Perlman, Douglas G. McNeel, Robert Jeraj, Glenn Liu

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Review Oncology

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Melissa Gamat-Huber, Donghwan Jeon, Laura E. Johnson, Jena E. Moseman, Anusha Muralidhar, Hemanth K. Potluri, Ichwaku Rastogi, Ellen Wargowski, Christopher D. Zahm, Douglas G. McNeel

CANCERS (2020)

Article Oncology

Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy

Alyssa A. Leystra, Brock J. Gilsdorf, Amanda M. Wisinger, Elise R. Warda, Shanna Wiegand, Christopher D. Zahm, Kristina A. Matkowskyj, Dustin A. Deming, Naghma Khan, Quincy Rosemarie, Chelsie K. Sievers, Alexander R. Schwartz, Dawn M. Albrecht, Linda Clipson, Hasan Mukhtar, Michael A. Newton, Richard B. Halberg

Summary: The study found that intestinal tumors with a multi-ancestral architecture involving at least two distinct clones exhibited increased growth and invasiveness, along with an impact on the response to low-dose aspirin. Genetically distinct tumor-founding cells can contribute to early intratumoral heterogeneity, enhancing colon tumor progression and affecting the response to aspirin.

CANCER REPORTS (2022)

Article Oncology

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy

Christopher D. Zahm, Jena E. Moseman, Lauren E. Delmastro, Douglas G. Mcneel

Summary: The study demonstrates that combining PD-1 and LAG-3 checkpoint blockade can further enhance the efficacy of anti-tumor vaccination, particularly showing the greatest effect in specific tumor models. This suggests that anti-tumor vaccination may be most effective when combined with concurrent blockade of both PD-1 and LAG-3, as well as potentially other checkpoint receptors whose expression is increased on CD8 + T cells following vaccine-mediated activation.

ONCOIMMUNOLOGY (2021)

Meeting Abstract Oncology

Low-dose targeted radionuclide therapy has favorable local and systemic effects on immune populations in a murine prostate cancer model

Hemanth Kumar Potluri, Reinier Hernandez, Christopher D. Zahm, Joseph Grudzinski, Christopher Massey, Jamey Weichert, Douglas G. McNeel

CANCER RESEARCH (2020)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Low-dose TRT reshapes the microenvironment of prostate tumors to potentiate response to immunotherapy

Reinier Hernandez, Hemanth Potluri, Eduardo Aluicio-Sarduy, Joseph Grudzinski, Christopher Massey, Christopher Zahm, Jonathan Engle, Douglas McNeel, Jamey Weichert

JOURNAL OF NUCLEAR MEDICINE (2020)

Meeting Abstract Oncology

Molecularly targeted radionuclide therapy modulates the composition of the murine prostate cancer microenvironment

Hemanth Potluri, Reinier Hernandez, Christopher Zahm, Joseph Grudzinski, Christopher Massey, Jamey Weichert, Douglas McNeel

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Meeting Abstract Oncology

Blockade of PD-1 and LAG-3 on CD8+T cells, induced by vaccination, elicits superior anti-tumor efficacy

Christopher Zahm, Douglas McNeel, Laurne Delmastro

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Meeting Abstract Oncology

Activation of CD8+T cells in the presence of multiple TLR agonists differently affects the expression of T-cell checkpoint receptors

Donghwan Jeon, Christopher Zahm, Douglas McNeel

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

90Y-NM600 targeted radionuclide therapy immunomodulates the tumor microenvironment of prostate tumors

R. Hernandez, C. Zahm, E. Aluicio-Sarduy, H. Potluri, J. Grudzinski, C. Massey, A. Bitton, J. Engle, D. McNeel, J. Weichert

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

Article Biology

90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma

Reinier Hernandez, Kirsti L. Walker, Joseph J. Grudzinski, Eduardo Aluicio-Sarduy, Ravi Patel, Christopher D. Zahm, Anatoly N. Pinchuk, Christopher F. Massey, Ariana N. Bitton, Ryan J. Brown, Paul M. Sondel, Zachary S. Morris, Jonathan W. Engle, Christian M. Capitini, Jamey P. Weichert

COMMUNICATIONS BIOLOGY (2019)

Article Oncology

Antibody and fragment-based PET imaging of CTLA-4+T-cells in humanized mouse models

Emily B. Ehlerding, Hye Jin Lee, Dawei Jiang, Carolina A. Ferreira, Christopher D. Zahm, Peng Huang, Jonathan W. Engle, Douglas G. McNeel, Weibo Cai

AMERICAN JOURNAL OF CANCER RESEARCH (2019)

暂无数据